Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
127005 trials found · Page 1931 of 6351
-
Spinal zaps and exercise may boost walking after injury
Symptom relief OngoingFor many people with spinal cord injury (SCI), the goal of walking is a high priority. There are many approaches available to restore walking function after SCI; however, these approaches often involve extensive rehabilitation training and access to facilities, qualified staff, a…
Sponsor: Shepherd Center, Atlanta GA • Aim: Symptom relief
Last updated Sep 03, 2026 00:00 UTC
-
Could a common diabetes drug ease leg pain for millions?
Symptom relief Recruiting nowPeripheral arterial disease (PAD) affects over 20% of aged adults and is very common among Veterans due significant tobacco use. PAD is due to the progressive blockage of peripheral arteries, predominantly to the legs, and results in intermittent claudication (IC) or recurrent mu…
Phase 3 • Sponsor: VA Office of Research and Development • Aim: Symptom relief
Last updated Jun 27, 2026 12:23 UTC
-
New hope for rare blood cancers: fedratinib shows promise in early trial
Disease control CompletedThe purpose of the study is to evaluate the effectiveness, safety, and tolerability of a study drug called fedratinib in participants with myelodysplastic/myeloproliferative neoplasms (MDS/MPNs) and chronic neutrophilic leukemia (CNL).
Phase 2 • Sponsor: H. Lee Moffitt Cancer Center and Research Institute • Aim: Disease control
Last updated Jun 27, 2026 13:04 UTC
-
Could viagra help COPD patients catch their breath?
Symptom relief Recruiting nowChronic obstructive pulmonary disease (COPD) is a condition characterized by airway obstruction. Patients with COPD experience significant shortness of breath on exertion. The mechanisms responsible for shortness of breath on exertion are well understood in moderate and severe CO…
Phase 2 • Sponsor: University of Alberta • Aim: Symptom relief
Last updated Jul 10, 2026 00:00 UTC
-
New asthma drug shows promise in Long-Term safety check
Disease control CompletedThe purpose of this open-label 12-month extension study is to continue to characterize the long-term safety, efficacy and immunogenic profile of GSK3511294 (Depemokimab) in participants with severe asthma with an eosinophilic phenotype following completion of clinical studies 206…
Phase 3 • Sponsor: GlaxoSmithKline • Aim: Disease control
Last updated Jun 27, 2026 08:11 UTC
-
Brain biotype may predict best antipsychotic drug
Disease control Recruiting nowThe CLOZAPINE study is designed as a multisite study across 5 sites and is a clinical trial, involving human participants who are prospectively assigned to an intervention. The study will utilize a stringent randomized, double-blinded, parallel group clinical trial design. B2 gro…
Phase 4 • Sponsor: University of Texas Southwestern Medical Center • Aim: Disease control
Last updated Jun 27, 2026 12:32 UTC
-
Chemo-Free combo for lymphoma shows promise in early trial
Disease control Stopped earlyFor marginal zone lymphoma (MZL) Rituximab in combination with conventional chemotherapy is widely used for those patients who fail local therapy or do not qualify for such. Depending on the MZL subtype Rituximab/chemotherapy is able to induce in part long remissions, but does no…
Phase 2 • Sponsor: University of Ulm • Aim: Disease control
Last updated Jun 27, 2026 09:09 UTC
-
Could a common steroid save lives in sepsis? new trial investigates
Disease control CompletedThe purpose of this study is to investigate the safety and efficacy of early administration of two different doses of dexamethasone in high risk septic patients.
Phase 1/2 • Sponsor: CHA University • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Can genes predict a dangerous complication of a common procedure?
Knowledge-focused Recruiting nowEndoscopic retrograde cholangiopancreatography (ERCP) comes with a risk for post-ERCP pancreatitis (PEP), which accounts for considerable morbidity, high healthcare expenditure, and death. The pathophysiology of PEP and the underpinnings of the preventive effect of rectal NSAID (…
Sponsor: Radboud University Medical Center • Aim: Knowledge-focused
Last updated Aug 23, 2026 00:00 UTC
-
Immune cells from cord blood aim to wipe out hidden colon cancer
Disease control CompletedA study of immunotherapy with expanded CB-NK cells in combination with cetuximab, to evaluate activity against minimal residual disease in patients with colon cancer that have completed adjuvant treatment but are positive for ctDNA
Phase 1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 08:15 UTC
-
A virtual clinic for lewy body dementia: could telehealth break down barriers to care?
Disease control OngoingLewy body dementia (LBD) is the 2nd most common neurodegenerative dementia in the US. Optimal care requires an interdisciplinary approach, however often faced barriers include rural residence, limited access to specialists, travel distance, limited awareness of resources, and phy…
Sponsor: University of Florida • Aim: Disease control
Last updated Aug 22, 2026 00:00 UTC
-
New hope for rare cervical cancer: drug trial targets tumor control
Disease control OngoingThis is a Phase 2, single center, open-label, single-arm study designed to evaluate the efficacy, safety, tolerability, and immunogenicity of AK104 monotherapy in adult subjects with previously treated recurrent or metastatic high grade neuroendocrine cervical cancer.
Phase 2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Aug 14, 2026 00:00 UTC
-
New drug targets brain inflammation to slow Alzheimer's
Disease control CompletedThe goal of this Phase 2 Alzheimer's study is to determine whether 1.0 mg/kg XPro1595 confers a benefit on cognition, function, and biomarkers of white matter and to further evaluate safety and tolerability. The objectives of this study are to determine the safety, tolerability, …
Phase 2 • Sponsor: Inmune Bio, Inc. • Aim: Disease control
Last updated Jul 01, 2026 00:00 UTC
-
Can a pill make CAR T-Cells last longer?
Disease control OngoingWhile chimeric antigen receptor T-cell (CAR T-cell) therapy produces impressive response rates in heavily pre-treated patients, early loss of response remains a barrier. One potential mechanism of relapse is limited CAR T-cell persistence. Pre-clinical research shows that PI3K in…
Phase 1 • Sponsor: Washington University School of Medicine • Aim: Disease control
Last updated Jun 27, 2026 09:02 UTC
-
Amniotic fluid shots aim to heal stubborn leg wounds
Disease control Recruiting nowDL-VSU-201 is a randomized, double-blind, placebo-controlled study in subjects with a non-infected venous stasis ulcer (VSU) that has failed to demonstrate improvement after receiving at least 4 weeks of standard, conventional wound therapy to evaluate the efficacy and safety of …
Phase 2 • Sponsor: Merakris Therapeutics • Aim: Disease control
Last updated Aug 28, 2026 00:00 UTC
-
Exercise may soothe chemo nerve pain, trial hopes
Symptom relief OngoingThis phase II trial studies whether using exercise is better than the usual approach for treating chemotherapy-induced peripheral neuropathy (CIPN). CIPN occurs when chemotherapy damages the nerves communicating between the brain, spinal cord, and the rest of the body. The usual …
Sponsor: University of Rochester NCORP Research Base • Aim: Symptom relief
Last updated Jun 27, 2026 12:23 UTC
-
Citizen scientists tackle drinking water contaminants in appalachia
Knowledge-focused Recruiting nowAppalachian Kentuckians in Martin and Letcher Counties are grappling with a health-threatening drinking water crisis arising from exposures to disinfection by-products (DBPs). DBPs include trihalomethanes (THMs), haloacetic acids (HAAs), chlorate, and other compounds that have be…
Sponsor: Anna Hoover • Aim: Knowledge-focused
Last updated Aug 29, 2026 00:00 UTC
-
New combo tackles Hard-to-Treat leukemia
Disease control Recruiting nowThis study combines vyxeos and gilteritinib in patients with relapsed or refractory FLT3-mutated acute myeloid leukemia. Vyxeos and gilteritinib will be given as induction therapy. Those patients entering a complete remission or a complete remission with incomplete blood count re…
Phase 1 • Sponsor: H. Lee Moffitt Cancer Center and Research Institute • Aim: Disease control
Last updated Jun 27, 2026 08:02 UTC
-
New radiation technique may make stem cell transplants safer for scleroderma patients
Disease control OngoingThis early phase I trial studies the side effects and feasibility of total body irradiation using intensity modulation radiation therapy (IMRT) when given in combination with cyclophosphamide prior to stem cell transplant to treat severe systemic sclerosis. IMRT delivers total bo…
Early phase 1 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated Aug 29, 2026 00:00 UTC
-
New daily pill for kids with ADHD shows promise in Long-Term safety trial
Disease control CompletedTo evaluate long-term safety exposure
Phase 3 • Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:34 UTC